Rida Hanan, Zaine Hind, Jouhadi Hassan, Benider Abdellatif, Samlali Hamza, Samlali Redouane
Department of Oncology-Radiotherapy, University Hospital Ibn Roch, Casablanca, Morocco.
Clinique d'oncologie le Littoral, Casablanca, Morocco.
Curr Urol. 2025 May;19(3):187-191. doi: 10.1097/CU9.0000000000000191. Epub 2023 Mar 28.
Renal cell carcinoma (RCC) has traditionally been considered to be radioresistant. Response rates are believed to be improved by a high dose of stereotactic body radiotherapy (SBRT). A retrospective analysis was conducted of patients treated with SBRT for metastatic disease from RCC.
We reviewed records from 20 patients who underwent SBRT for a total of 30 RCC metastases from 2015 to 2020. Patients were included who had a confirmed primary RCC and radiographic evidence of metastasis, either synchronous or metachronous. The most common SBRT fractionation was 30 Gy in 3 fractions.
Median age was 60 years (range, 40-77 years) and 60% were male. After a median follow-up of 18 months (range, 3-36 months), overall survival was estimated to be 85% and 70%, at 1 and 2 years, respectively, and local control at 2 years was 83.33%. Only 5 patients had documented progression of disease, all of whom received biologically effective dose inferior to 100 Gy, and no patients treated with a higher biologically effective dose had disease, which progressed. The most common acute toxicity was grade 1 fatigue (20%). No grade 3 or higher acute toxicity occurred.
Treatment with SBRT in patients with RCC metastases yielded a high local control rate, promising survival rate, and low toxicity.
肾细胞癌（RCC）传统上被认为具有放射抗性。据信，高剂量立体定向体部放疗（SBRT）可提高缓解率。对接受SBRT治疗的RCC转移性疾病患者进行了回顾性分析。
我们回顾了2015年至2020年期间20例接受SBRT治疗的患者的记录，这些患者共有30处RCC转移灶。纳入的患者有确诊的原发性RCC以及转移的影像学证据，包括同时性或异时性转移。最常见的SBRT分割方案是分3次给予30 Gy。
中位年龄为60岁（范围40 - 77岁），60%为男性。中位随访18个月（范围3 - 36个月）后，1年和2年的总生存率分别估计为85%和70%，2年的局部控制率为83.33%。只有5例患者记录有疾病进展，所有这些患者接受的生物等效剂量均低于100 Gy，而接受更高生物等效剂量治疗的患者均无疾病进展。最常见的急性毒性为1级疲劳（20%）。未发生3级或更高等级的急性毒性。
SBRT治疗RCC转移患者可产生较高的局部控制率、良好的生存率和较低的毒性。
